top of page

Vyne Therapeutics' CEO describes the rationale for using BET inhibition in autoimmune diseases

David Domzalski discusses how Vyne is using this target that is traditionally thought of in oncology in a topical form for vitiligo and an oral therapy for RA and psoriasis.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page